Newfound Effect of Cancer Drug May Expand its Use
A drug first designed to prevent cancer cells from multiplying has a second effect: it switches immune cells that turn down the body’s attack on tumors back into the kind that amplify it. The study, led by researchers from NYU Langone Medical Center and recently published in Cancer Immunology Research, shows that the drug nab-paclitaxel (brand name Abraxane®) elicits an aggressive anti-tumor immune response. “Our study reveals a previously unappreciated role for Abraxane® in tumor immunology,” says corresponding author Dafna Bar-Sagi, PhD.
Transcranial Direct Current Stimulation Combined with Computer Games at Home Reduces Cognitive Symptoms of Multiple Sclerosis
People with multiple sclerosis (MS) had better problem solving ability and response time after training with a technology called transcranial direct current stimulation (tDCS), according to a new study recently published in Neuromodulation: Technology at the Neural Interface. “Our research adds evidence that tDCS, while done remotely under a supervised treatment protocol, may provide an exciting new treatment option for people with multiple sclerosis who cannot get relief for some of their cognitive symptoms,” says lead researcher Leigh E. Charvet, PhD.